×
About 30,640 results

'Call to Action' for DPYD Testing Before Fluorouracil Chemo
https://www.medscape.com/viewarticle/984799

Dec 1st, 2022 - The debate over whether or not to test for DPYD gene variants before administering fluoropyrimidine (FP) chemotherapy has erupted again among experts in the United States, where such testing is not recommended at present, unlike in Europe. Testing for DPYD variants and subsequent dose adjustment should be offered to US patients who are due to receive fluoropyrimidine chemotherapy, says Daniel L...

Tamoxifen Ups Risk of Uterine Disease, Endometrial Cancer
https://www.medscape.com/viewarticle/984846

Dec 1st, 2022 - Tamoxifen treatment for premenopausal women with breast cancer is independently associated with an increased risk of endometrial cancer and other uterine diseases, according to findings from a large retrospective study of Korean women. After adjusting for multiple confounding variables, tamoxifen users had an almost fourfold increased risk of endometrial cancer compared with nonusers. Overall, ...

AstraZeneca Boosts Cancer Portfolio With $320 Million Neogene Deal
https://www.medscape.com/viewarticle/984703

Nov 30th, 2022 - (Reuters) -AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals su...

Late-Stage CRC Spiked in Second Year of Pandemic
https://www.medscape.com/viewarticle/984756

Nov 30th, 2022 - Diagnoses of late-stage colorectal cancer (CRC) increased substantially during the COVID-19 pandemic, according to a review of almost 18,000 patients at 81 medical centers in Italy. There was an increase in locally advanced cancers during the first year of the pandemic in 2020, but this was followed by "a more definitive increase [in] advanced cases," particularly metastatic disease, in the sec...

Who's More Likely to Develop a Second Primary Melanoma?
https://www.medscape.com/viewarticle/984768

Nov 30th, 2022 - Individuals with a primary melanoma may be more likely to develop a second primary melanoma if they have certain characteristics, a new study suggests. In a cohort study of more than 38,000 patients, those diagnosed with a second primary melanoma were significantly more likely to have a "nevus-prone" phenotype and a high polygenic risk score for melanoma. Notably, the researchers also found onl...

Latinx and Melanoma: Barriers and Opportunities
https://www.medscape.com/viewarticle/984769

Nov 30th, 2022 - Latinx individuals have a lower overall risk of melanoma than non-Latinx Whites (NLW), but they are more likely to be diagnosed with advanced disease, and experience greater mortality. A new qualitative study of Latinx and low-income NLW individuals in California has revealed some of the socioeconomic and community factors that may play a role in preventing early access to care. Thicker melanom...

Racial Disparities in Lung Cancer Start With Research
https://www.medscape.com/viewarticle/984774

Nov 30th, 2022 - During a routine visit to the Good Samaritan Clinic in Morganton, North Carolina, in 2018, Herbert Buff casually mentioned that he sometimes had trouble breathing. He was 55 years old and a decades-long smoker. So the doctor recommended that Buff schedule time on a 35-foot-long bus operated by the Levine Cancer Institute that would roll through town later that week offering free lung-cancer scr...

AFib Risk Rises as A1c Increases
https://www.medscape.com/viewarticle/984714

Nov 29th, 2022 - Researchers published the study covered in this summary on Research Square as a preprint that has not yet been peer reviewed. Key Takeaways Adults not receiving glucose-lowering drugs showed a stepwise, increasing risk of developing atrial fibrillation (AFib) that tracked with increasing levels of A1c from 5.8% to 7.6% (40 to 60 mmol/mol). Patients with new-onset diabetes had a similar risk of ...

Stool Transplants May Boost Immunotherapy Success in Melanoma
https://www.medscape.com/viewarticle/984710

Nov 29th, 2022 - In advanced and metastatic melanoma patients, fecal microbiota transplant (FMT) from healthy donors in advance of anti–PD-1 immunotherapy led to a 75% clinical benefit rate, defined as complete response, partial response, or stable disease that lasted 6 months or longer. The results come from a small, single arm phase 1 study whose primary endpoint was safety. "We know that the gut microbiome h...

Atezolizumab (Tecentriq) Bladder Cancer Indication Withdrawn in US
https://www.medscape.com/viewarticle/984722

Nov 29th, 2022 - Atezolizumab (Tecentriq) is no longer approved in the United States for use in certain patients with bladder or urinary tract cancer. The drug is an anti-PD-L1 inhibitor immunotherapy, and continues to be approved for use in lung and liver cancer and melanoma. The manufacturer, Genentech, announced that it was voluntarily withdrawing the US indication for atezolizumab that covered its use in  a...

Pregnancy Not a Barrier to Interventional Cardiology Career
https://www.medscape.com/viewarticle/984724

Nov 29th, 2022 - A new collaborative position paper on radiation exposure during pregnancy states that pregnant women can safely work in an ionizing radiation environment if exposure to the fetus does not exceed certain dose thresholds. The position paper aims to "avoid discouraging" women from pursuing careers in interventional cardiology/electrophysiology (IC/EP) and to "dismantle" a barrier that says, "activ...

'Just Some Eccentric Guy in Australia': The Story of a Non-retraction for Plagiarism
https://www.medscape.com/viewarticle/984719

Nov 29th, 2022 - After reading a paper published in The Annals of the Royal College of Surgeons of England last March, Andrew Thomas, an orthopedic surgeon in the UK, noticed that it was very similar to an article published the previous December in another journal. He wrote a letter to the editor of Annals, notifying the journal of the similarity between its paper, "The possible effect of different types of ven...

'Something Good After Tragic Loss': Donating Brain Cancer Tissue
https://www.medscape.com/viewarticle/984624

Nov 28th, 2022 - "Have you considered tissue donation?" These "five simple words" could have profound impact for pediatric brain cancer research — and for children with brain cancer and their families, according to pediatric neuro-oncologist Vijay Ramaswamy, MD, PhD, at The Hospital for Sick Children in Toronto, Canada. However, families who have lost a child to brain cancer often aren't made aware of the optio...

Transgender Patients on Hormone Therapy Require Monitoring
https://www.medscape.com/viewarticle/984631

Nov 28th, 2022 - PAU, France — Transgender patients on hormone therapy have an increased mortality risk, compared with the general population, and so must be closely monitored, especially in terms of cardiovascular health and oncology, reported Marie D'Assigny, MD, of the Department of Endocrinology, Diabetes and Dietetics at Poitiers University Hospital, Poitiers, France at the Infogyn 2022 conference. Since t...

Just 8 Minutes of Exercise a Day Is All You Need
https://www.medscape.com/viewarticle/984684

Nov 28th, 2022 - You can get all the exercise you need in just 8 minutes a day if you work out a bit harder, according to a new study in the European Heart Journal. Just 54 minutes of vigorous exercise per week provides the most bang for your buck, researchers found, lowering the risk of early death from any cause by 36%, and your chances of getting heart disease by 35%. Scientists examined data from fitness tr...

Lung Cancer Screening Pushes 20-Year Survival Rate to 80%
https://www.medscape.com/viewarticle/984688

Nov 28th, 2022 - CHICAGO — Discovering lung cancer early with annual low-dose computed tomography greatly improves long-term survival rates to 80%, findings from a 20-year international study indicate. Dr Claudia Henschke Claudia Henschke, MD, PhD, professor of radiology and director of the Early Lung and Cardiac Action Program (ELCAP) at the Icahn School of Medicine at Mount Sinai in New York City, presented r...

Debating the Clinical Trial Upending Colonoscopy Practices
https://www.medscape.com/viewarticle/983886

Nov 28th, 2022 - This transcript has been edited for clarity. F. Perry Wilson, MD, MSCE: Hello, and thank you for joining us today for what promises to be a lively discussion about screening for colon cancer. My name is Perry Wilson. I’m an associate professor of medicine and director of the Clinical and Translational Research Accelerator at the Yale School of Medicine. My new book, How Medicine Works and When ...

FDA Rejects Poziotinib for Certain Types of NSCLC
https://www.medscape.com/viewarticle/984604

Nov 25th, 2022 - The US Food and Drug Administration (FDA) has announced that it will not approve poziotinib (Spectrum Pharmaceuticals) for the treatment of certain patients with nonsmall-cell lung cancer (NSCLC). The clinical data that the company had submitted was deemed insufficient for approval, and additional data including a randomized clinical trial would be needed, the agency said. The move is not a sur...

Managing T-DXd Adverse Events in the Real World
https://www.medscape.com/viewarticle/984603

Nov 25th, 2022 - With recent expansions in its breast cancer indications, there has been an increase in the use of trastuzumab deruxtecan (T-DXd; Enhertu). "A lot of us are using this more frequently now than we were in the past," explained Sid Yadav, MD, a breast and gynecologic cancer specialist at the Mayo Clinic in Rochester, Minnesota. However, he added that managing its adverse events has been a "bit of a...

FDA Requests More Restrictions on Ovarian Cancer Drugs
https://www.medscape.com/viewarticle/984547

Nov 23rd, 2022 - The US Food and Drug Administration (FDA) is moving to further restrict the use of certain PARP inhibitors in patients with ovarian cancer, citing recent data showing an increased risk for death with the agents versus chemotherapy. These restrictions could mean bankruptcy for one company. Earlier this year, several companies voluntarily withdrew their respective PARP inhibitors for heavily pret...